Compare Zimmer Biomet Holdings Inc (ZBH) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Zimmer Biomet Holdings Inc vs Zscaler Inc — how do they compare? Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.55B), while Zscaler Inc trades at $176.92 (market cap $28.87B). The key difference: Zscaler Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 0.99% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals.
| ZBH | ZS | |
|---|---|---|
Market Cap | $18.55B | $28.87B |
Sector | Health | Technology |
52-Week High | $107.71 | $336.27 |
52-Week Low | $79.58 | $118.05 |
Enterprise Value | $25.61B | $27.20B |
Dividend Yield | 0.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Zimmer Biomet (ZBH) trades at $97.9, up 0.12% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology. Key financials show a P/E of 23.6 and net income margin of 9.48%, while cash flow from operations improved to $1.70B in 2025.
The outlook is positive, with a consensus price target of $103.56 offering ~6% upside. Risks include competitive pressures and margin volatility, but consistent earnings beats and institutional accumulation support a constructive view for long-term investors.
Zscaler (ZS) trades at $176.94, up 0.15% with strong bullish technical signals and positive analyst sentiment. The stock shows consistent revenue growth from $1.1B in 2022 to $2.67B in 2025, though it remains unprofitable with a -2.44% net margin. Recent earnings beats and leadership in Gartner Magic Quadrant for SASE platforms highlight operational strength. Current price sits near resistance at $177 with RSI indicating overbought conditions.
Outlook remains positive with 79% analyst buy ratings and $191.81 consensus target, but risks include negative profitability, high valuation multiples (P/S 8.94), and projected negative cash flow in 2026. The cybersecurity leader benefits from AI-driven security demand but faces execution risks amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
